Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record.

Safety and efficacy of combination therapies including cilofexor/ firsocostat in patients with bridging fibrosis and cirrhosis due to NASH: Results of the phase 2b ATLAS trial

Overview

Integrity signals

Registry

Crossref · 10.1016/s0168-8278(20)30753-4

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cited by

See all 9

Metadata

Authors
Loomba, R., Noureddin, M., Kowdley, K., Kohli, A., Sheikh, A., Neff, G., Bhandari, B. R., Gunn, N. T., Caldwell, S., Goodman, Z., Wapinski, I., Resnick, M., Beck, A., Ding, D., Jia, C., Huss, R., Chung, C., Subramanian, M., Myers, R., Patel, K., Borg, B., Ghalib, R., Kabler, H., Poulos, J., Younes, Z. H., Elkhashab, M., Hassanein, T., Iyer, R., Ruane, P., Shiffman, M., Strasser, S., Wong, V. W.-S., & Alkhouri, N.
Affiliations
  • University of California San Diego (US)
  • Cedars-Sinai Medical Center (US)
  • Liver Institute Northwest (US)
  • Arizona Liver Health (US)
  • GI Specialists of Georgia (United States) (US)
  • Covenant Research and Clinics (United States) (US)
  • Pinnacle Clinical Research (US)
  • University of Virginia (US)
  • Inova Fairfax Hospital (US)
  • PathAI (United States) (US)
  • Gilead Sciences (United States) (US)
  • University of Toronto (CA)
  • Centre Hospitalier Universitaire de Nice (FR)
  • Centre Hospitalier Universitaire de Nantes (FR)
  • Cumberland Research Associates (United States) (US)
  • Centre Hospitalier Universitaire de Poitiers (FR)
  • Centre Hospitalier Universitaire Amiens-Picardie (FR)
  • Iowa Digestive Disease Center (US)
  • Ruane Medical (US)
  • Bon Secours Mercy Health (US)
  • The University of Sydney (AU)
  • Chinese University of Hong Kong (HK)
  • Texas Liver Institute (US)
Corresponding author
Huss, Ryan
Venue
Journal of Hepatology
Publisher
Elsevier BV
Published
2020-08
Volume
73
Pages
S116-S117
ISSN
0168-8278 (ISSN-L)
OpenAlex
W4246217891
Cited by
9
References
0
Citations by year
2022: 2 · 2021: 7
FWCI
1.62
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
Journal of Hepatology (publishedVersion)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Surgery › Organ Transplantation Techniques and Outcomes
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
Keywords
severe alcoholic hepatitis, early liver transplantation, non-inferiority, alcohol relapse, Lille score, MELD score, heavy drinking, post-transplant survival, alcoholic cirrhosis, NASH, liver cirrhosis, fibrosis, combination therapy, ATLAS trial

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety and efficacy of combination therapies including cilofexor/ firsocostat in patients with bridging fibrosis and cirrhosis due to NASH: Results of the phase 2b ATLAS trial. https://app.cochat.ai/papers/10.1016/s0168-8278(20)30753-4
The paper
Loomba, R., Noureddin, M., Kowdley, K., Kohli, A., Sheikh, A., Neff, G., Bhandari, B. R., Gunn, N. T., Caldwell, S., Goodman, Z., Wapinski, I., Resnick, M., Beck, A., Ding, D., Jia, C., Huss, R., Chung, C., Subramanian, M., Myers, R., . . . Alkhouri, N. (2020). Safety and efficacy of combination therapies including cilofexor/ firsocostat in patients with bridging fibrosis and cirrhosis due to NASH: Results of the phase 2b ATLAS trial. Journal of Hepatology. https://doi.org/10.1016/s0168-8278(20)30753-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.